Recro Pharma Inc (REPH) Given Consensus Recommendation of “Buy” by Brokerages

Recro Pharma Inc (NASDAQ:REPH) has received an average recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $11.38.

A number of equities analysts have weighed in on the company. Roth Capital reissued a “neutral” rating and set a $7.50 price target (down previously from $15.00) on shares of Recro Pharma in a research report on Monday, March 25th. Oppenheimer reissued an “outperform” rating and set a $9.00 price target (down previously from $19.00) on shares of Recro Pharma in a research report on Monday, March 25th. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a research report on Wednesday, January 9th. ValuEngine downgraded Recro Pharma from a “buy” rating to a “hold” rating in a research report on Monday, March 25th. Finally, Janney Montgomery Scott reissued a “buy” rating and set a $13.00 price target on shares of Recro Pharma in a research report on Thursday, January 31st.

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC grew its position in shares of Recro Pharma by 26.0% in the third quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock valued at $3,416,000 after purchasing an additional 99,200 shares during the last quarter. Monarch Partners Asset Management LLC grew its position in shares of Recro Pharma by 57.4% in the fourth quarter. Monarch Partners Asset Management LLC now owns 55,857 shares of the specialty pharmaceutical company’s stock valued at $397,000 after purchasing an additional 20,367 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Recro Pharma in the third quarter valued at approximately $156,000. Rhumbline Advisers grew its position in shares of Recro Pharma by 47.8% in the fourth quarter. Rhumbline Advisers now owns 23,753 shares of the specialty pharmaceutical company’s stock valued at $169,000 after purchasing an additional 7,679 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its position in shares of Recro Pharma by 1,361.1% in the third quarter. Panagora Asset Management Inc. now owns 189,128 shares of the specialty pharmaceutical company’s stock valued at $1,345,000 after purchasing an additional 176,184 shares during the last quarter. 55.34% of the stock is currently owned by institutional investors.

NASDAQ REPH traded down $0.03 during trading on Monday, reaching $8.34. 2,097 shares of the company’s stock were exchanged, compared to its average volume of 984,701. The company has a market cap of $184.94 million, a PE ratio of -3.37 and a beta of -0.36. The company has a quick ratio of 2.08, a current ratio of 2.45 and a debt-to-equity ratio of 4.04. Recro Pharma has a fifty-two week low of $4.78 and a fifty-two week high of $13.05.

Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings results on Tuesday, February 19th. The specialty pharmaceutical company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.17. The firm had revenue of $17.78 million for the quarter, compared to the consensus estimate of $16.01 million. Recro Pharma had a negative return on equity of 472.58% and a negative net margin of 103.07%. As a group, research analysts anticipate that Recro Pharma will post -1.94 EPS for the current fiscal year.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Article: Buyback

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.